Chronic Myelomonocytic Leukemia Epidemiology Forecast

DelveInsight's ‘Chronic Myelomonocytic Leukemia (CMML) — Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Myelomonocytic Leukemia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Chronic Myelomonocytic Leukemia Disease Understanding

The DelveInsight’s Chronic Myelomonocytic Leukemia market report gives a thorough understanding of Chronic Myelomonocytic Leukemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Chronic Myelomonocytic Leukemia is a rare, clonal hematopoietic stem cell disorder characterized by the presence of sustained (>3 months) peripheral blood (PB) monocytosis (≥1 × 109/L; monocytes ≥10% of white blood cell count) along with dysplastic features in the bone marrow (BM). Since CMML has similar features as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN), the WHO classifies it as being a mixture of these two conditions, termed as a myelodysplastic syndrome/myeloproliferative neoplasm.

The exact cause of CMML is unknown, but there are certain risk factors which are thought to make a person more likely to develop the disease. They are old age and being of the male sex. At times, CMML is also caused by radiotherapy or chemotherapy treatment for cancer (secondary or treatment related CMML). Certain genetic changes are also thought to be responsible for this disease, like changes in TET2 gene, changes in RAS gene, changes in ASXL1 gene, etc.

CMML is a slowly progressing disease, which often does not show any symptoms at first; but patients might later develop some signs and symptoms like spleen enlargement, anemia, frequent infections, skin rashes or lumps, pleural effusion, etc. CMML also shares clinical and biological features with MDS, including cytopenia and bone marrow failure, risk of progression to AML, and overlapping, recurring, cytogenetic abnormalities.

Diagnosis

CMML is diagnosed on a number of confirmatory tests, like Complete Blood Count, Blood Smear, Bone marrow aspiration and biopsy, and also cytogenic testing for observation of cell DNA abnormalities.

The World Health Organisation (WHO) has split CMML into 3 types, type 0, type 1 and type 2, which are decided on the basis of the number of abnormal myeloid cells present in the patient’s blood and bone marrow.

• Type 0 CMML: less than 2% blast cells in the patient’s blood and less than 5% blast cells in their bone marrow
• Type 1 CMML: 2-4% blast cells in the patient’s blood or 5-9% blasts in their bone marrow, some patients have both
• Type 2 CMML: 5-19% blast cells in the patient’s blood and 10-19% in their bone marrow

Chronic Myelomonocytic Leukemia Epidemiology

The Chronic Myelomonocytic Leukemia epidemiology section provides insights about historical and current Chronic Myelomonocytic Leukemia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

According to Surveillance, Epidemiology, and End Results Program (SEER), in 2019, the incidence of Chronic Myelomonocytic Leukemia in males was 0.8 per 100,000 and in females was 0.3 per 100,000 in the US. There was also a clear age predominance observed where the median age of diagnosis was observed to be 65-75 years, with the incidence reaching 3.5 per 100,000 in 2019 in the 65+ age group, unlike the 0.3 and negligible incidence of CMML in 2019 in the 50–64 and <50 age groups respectively.

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Myelomonocytic Leukemia epidemiology [segmented as Incident cases of Chronic Myelomonocytic Leukemia, Type-specific Cases of Chronic Myelomonocytic Leukemia, Age-specific Cases of Chronic Myelomonocytic Leukemia, Gender-specific Cases of Chronic Myelomonocytic Leukemia, Mutation-specific Cases of Chronic Myelomonocytic Leukemia and Treated Cases of of Chronic Myelomonocytic Leukemia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- Chronic Myelomonocytic Leukemia Epidemiology

This section provides glimpse of the Chronic Myelomonocytic Leukemia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

KOL- Views

To keep up with the current Chronic Myelomonocytic Leukemia patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Chronic Myelomonocytic Leukemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

• The report covers the descriptive overview of Chronic Myelomonocytic Leukemia, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Chronic Myelomonocytic Leukemia
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Incident cases of Chronic Myelomonocytic Leukemia, Type-specific Cases of Chronic Myelomonocytic Leukemia, Age-specific Cases of Chronic Myelomonocytic Leukemia, Gender-specific Cases of Chronic Myelomonocytic Leukemia, Mutation-specific Cases of Chronic Myelomonocytic Leukemia and Treated Cases of of Chronic Myelomonocytic Leukemia

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myelomonocytic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Myelomonocytic Leukemia
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Learn how the therapeutic market will evolve and grow in the coming years: Chronic Myelomonocytic Leukemia Market
 

Chronic Myelomonocytic Leukemia Report Insights

• Patient Population
• Therapeutic Approaches

Chronic Myelomonocytic Leukemia Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Chronic Myelomonocytic Leukemia Epidemiology Segmentation

Chronic Myelomonocytic Leukemia Report Assessment

• Disease Understanding
• Current Diagosis Practices and Guidelines
• Epidemiology Trends

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Chronic Myelomonocytic Leukemia?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Chronic Myelomonocytic Leukemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Chronic Myelomonocytic Leukemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Chronic Myelomonocytic Leukemia?
• Out of all 7MM countries, which country would have the highest incident population of Chronic Myelomonocytic Leukemia during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Chronic Myelomonocytic Leukemia Disease market
• To understand the future market competition in the Chronic Myelomonocytic Leukemia Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Chronic Myelomonocytic Leukemia Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Chronic Myelomonocytic Leukemia Disease market
• To understand the future market competition in the Chronic Myelomonocytic Leukemia Disease market